NCT05218499 2026-03-02
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 2/3 Completed
Boehringer Ingelheim
National Cancer Institute (NCI)
Universitätsklinikum Hamburg-Eppendorf
GBG Forschungs GmbH
French Innovative Leukemia Organisation
Lymphoma Study Association